This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $72.79 in the latest trading session, marking a +0.78% move from the prior day.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $74.06, moving -1.41% from the previous trading session.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Penumbra (PEN) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.
Hologic (HOLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 5.68% and 2.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra
by Zacks Equity Research
Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $81.32, marking a +0.54% move from the previous day.
Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.
Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.
QIAGEN (QGEN) Expands Digital PCR Offering With New Pact
by Zacks Equity Research
QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
NextGen (NXGN) Settles Misrepresentation Allegations for $31M
by Zacks Equity Research
NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $78.96 in the latest trading session, marking a -1.69% move from the prior day.
Boston Scientific (BSX) Gets FDA Nod for Vercise Software
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.